Want to see FR:ABVX full AI Analyst Report?
Top Page
Abivax SA
(ABVX)
Select Model
Select Model
Rating:47Neutral
Price Target:
€133.00
▲(27.03% Upside)
Action:Reiterated
Date:07/01/26
The score is primarily held down by weak financial performance driven by substantial losses and persistent cash burn. Valuation is also pressured because negative earnings make the P/E less informative and there is no dividend yield provided. Technicals are neutral due to missing indicator data.
Positive Factors
Balance sheet improvement
Meaningful 2025 equity increase and low leverage (~7% debt/equity) provide durable financing flexibility over the next several quarters, lowering near-term refinancing pressure. This supports continued R&D spend and trial execution without immediate insolvency risk, improving operational resilience.
Negative Factors
Persistent cash burn
Sustained annual negative operating and free cash flows, including ~-162M in 2025, means the company lacks internal cash generation to fund ongoing R&D. Over 2–6 months this forces reliance on external financing, raising dilution risk and constraining strategic optionality if markets tighten or fundraises are delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet improvement
Meaningful 2025 equity increase and low leverage (~7% debt/equity) provide durable financing flexibility over the next several quarters, lowering near-term refinancing pressure. This supports continued R&D spend and trial execution without immediate insolvency risk, improving operational resilience.
Read all positive factors
Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)
Market Cap
€10.69B
Dividend YieldN/A
Average Volume (3M)99.97K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue GrowthN/A
EPS GrowthN/A
CountryFR
Employees69
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.83
Shares Outstanding87,160,670
10 Day Avg. Volume99,142
30 Day Avg. Volume99,970
Financial Highlights & Ratios
PEG Ratio-0.34
Price to Book (P/B)18.39
Price to Sales (P/S)0.00
P/FCF Ratio-51.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€130.00Price Target Upside24.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.29
Revenue Forecast (FY)€3.81M
Abivax SA Business Overview & Revenue Model
Company Description
Abivax S.A. is a Paris-based pharmaceutical firm, established in 2013, dedicated to identifying and refining treatments for various serious conditions, including inflammatory and infectious diseases, as well as cancer. Its primary drug candidate, ...
How the Company Makes Money
Abivax SA does not have a disclosed commercial product revenue stream and, as a clinical-stage biopharmaceutical company, its operations are primarily funded through external financing rather than sales. The company’s cash inflows typically come f...
Abivax SA Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 10.79M | 4.62M | 4.58M | 37.00K |
| Gross Profit | -1.07M | 10.79M | 4.49M | 4.51M | -119.00K |
| EBITDA | -249.55M | -167.68M | -133.21M | -53.31M | -42.20M |
| Net Income | -336.10M | -176.24M | -147.74M | -60.74M | -42.45M |
Balance Sheet | |||||
| Total Assets | 584.34M | 205.23M | 327.06M | 73.35M | 110.36M |
| Cash, Cash Equivalents and Short-Term Investments | 530.38M | 144.22M | 260.99M | 26.95M | 60.70M |
| Total Debt | 32.09M | 97.36M | 55.46M | 39.16M | 53.45M |
| Total Liabilities | 129.14M | 164.64M | 131.05M | 71.47M | 81.59M |
| Stockholders Equity | 455.20M | 40.58M | 196.01M | 7.19M | 25.93M |
Cash Flow | |||||
| Free Cash Flow | -162.23M | -154.72M | -97.39M | -69.55M | -47.30M |
| Operating Cash Flow | -162.09M | -154.07M | -97.13M | -65.58M | -45.66M |
| Investing Cash Flow | -13.72M | 15.76M | -8.10M | -3.73M | -1.46M |
| Financing Cash Flow | 553.80M | 28.21M | 335.29M | 32.21M | 82.68M |
Abivax SA Technical Analysis
Positive
104.70
Price Trends
99.67
Positive
100.55
Positive
97.99
Positive
Market Momentum
9.15
Negative
63.76
Neutral
74.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Positive. The current price of 104.7 is above the 20-day moving average (MA) of 100.50, above the 50-day MA of 99.67, and above the 200-day MA of 97.99, indicating a bullish trend. The MACD of 9.15 indicates Negative momentum. The RSI at 63.76 is Neutral, neither overbought nor oversold. The STOCH value of 74.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABVX.
Abivax SA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | €149.49M | -2.86 | -658.91% | ― | -77.92% | 11.11% | |
48 Neutral | €207.04M | -2.91 | -634.16% | ― | 291.43% | 12.24% | |
47 Neutral | €10.69B | -25.42 | ― | ― | ― | ― | |
43 Neutral | €195.42M | -4.39 | -30.75% | ― | 32.62% | -7.59% | |
42 Neutral | €843.60M | -3.36 | -241.12% | ― | ― | 27.51% | |
42 Neutral | €433.72M | -2.69 | -58.93% | ― | -15.98% | -54.34% |
* General Sector Average
FR:ABVX
Abivax SA
122.90
115.79
1628.55%
FR:IPH
Innate Pharma SA
1.57
0.07
4.79%
FR:DBV
DBV Technologies
2.85
1.00
54.00%
FR:TNG
Transgene
0.76
-0.03
-3.69%
FR:VLA
Valneva
2.18
-0.34
-13.39%
FR:ALCLS
Cellectis SA
2.59
1.23
91.00%
Abivax SA Corporate Events
Abivax’s obefazimod hits key phase 3 targets in ulcerative colitis
Jun 1, 2026
Abivax reported positive topline results from its global phase 3 ABTECT maintenance trial of obefazimod in adults with moderate to severe ulcerative colitis, where both 25 mg and 50 mg once-daily doses achieved significantly higher week-44 clinica...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.